Head-to-head · WeighScore
Medro vs Voxy
The verdict
Medro takes it — 63.6/100 to 62.1/100, but only just.
Medro grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Medro (Medro Health Technologies, Inc.) is a telehealth brand whose GLP-1 program offers compounded semaglutide and tirzepatide, plus brand-name GLP-1s when eligible, via a partner medical group and… Voxy is close behind and may still be the better fit — see the factor split below.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Medro | Voxy |
|---|---|---|
| WeighScore | 63.6/100 | 62.1/100 |
| Grade | C | C |
| Scorecard rank | #256 | #280 |
| Semaglutide | $199/mo (compounded) | $179/mo (compounded) |
| Tirzepatide | $299/mo (compounded) | $299/mo (compounded) |
| Coverage | All 50 states | Coverage not published |
| Brand-name access | Yes | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #256 · C
Strengths
- Covers both compounded semaglutide and tirzepatide and can prescribe brand-name GLP-1s when clinically appropriate.
- LegitScript-certified (seal #50716646), available in all 50 states, with tiered pricing shown before checkout.
- No membership fee and free expedited shipping on all orders; online intake with no appointment required in many cases.
- Prices drop with longer commitments (semaglutide to $149/mo, tirzepatide to $224/mo on a 12-month plan).
Where it loses points
- Does not name its compounding pharmacy or its clinical partner medical group, so the fulfillment chain is not verifiable.
- Pricing is described as illustrative and may change by dose, pharmacy availability, and eligibility — final cost shows only at checkout.
- Very new brand (2026, trademark pending) spanning many verticals, with a short track record in GLP-1 care.
- Compounded medications are not FDA-approved or therapeutically equivalent to Ozempic, Wegovy, Mounjaro, or Zepbound.
Graded #280 · C
Strengths
- Names both its compounding pharmacy (VialsRX, Houston TX) and its prescribing medical group (Arora Health & Aesthetics) — most name neither
- Publishes the full price ladder for both drugs across 1-, 3-, 6- and 12-month terms before you start the assessment
- One price covers the provider visit, medication, injection supplies, shipping and monthly check-ins — no separate membership fee
- True month-to-month option at $179 semaglutide / $299 tirzepatide with no commitment required
- Free assessment with no charge to see if you qualify, and no labs required to start
Where it loses points
- No terms of service anywhere on the site — /terms, /terms-of-service and /terms-of-use all return 404
- No refund policy published; the only stated commitment language is 'cancel anytime'
- Advertised 'Starting at $129/mo' is the 12-month prepay rate — month-to-month is $179 semaglutide and $299 tirzepatide
- No public list of states served; availability depends on where affiliated providers are licensed
- The prescribing nurse practitioner is not named — 'provider details available during your consultation'
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.